Discover Multi-Asset Margin Mode on MEXC, which enhances your capital efficiency and enables risk management with ease.In this video, you’ll learn:✅ What is the Multi-Asset Margin Mode✅ How to enable it on MEXC✅ Key notes and restrictions👇 Watch and enable now: https://t.co/pmVnBdIA02 ...

Plus, a first-of-its-kind metric: Capital Efficiency- Compare circulating stablecoin supply vs. protocol revenue- See which networks are actually monetizing stablecoin activity https://t.co/X1gM9dueON ...

Core Viewpoint - General Motors announced a $1.6 billion charge in its third-quarter earnings, linked to a strategic realignment of its electric vehicle (EV) production plans, which reflects proactive leadership rather than failure [3][4][6] Financial Impact - The $1.6 billion charge consists of approximately $1.2 billion in non-cash impairment for underutilized EV-related assets and about $400 million in cash costs to exit specific supplier contracts [6] - The company is trading at a P/E ratio of 9.19 and has a dividend yield of 1.04%, with a price target of $65.00, indicating potential upside [3][11] Market Dynamics - The charge is a response to two key market shifts: the moderation of government-incentivized EV adoption and the expiration of federal EV tax credits, which have reduced consumer purchasing incentives [7][8] - GM is prioritizing fiscal discipline by adjusting production schedules to align with actual consumer demand, avoiding overproduction that could erode margins [9] Core Business Strength - GM's traditional internal combustion engine (ICE) vehicles continue to generate significant cash flow, supporting the transition to EVs and shareholder returns [10] - In Q3, GM's U.S. vehicle sales increased by 8% year-over-year, with a total of 2.2 million vehicles sold in the first nine months of 2025, demonstrating strong consumer demand [14] Strategic Partnerships - GM has partnered with Hyundai to co-develop five new vehicles, aiming for 800,000 annual vehicle sales, which reflects a low-cost strategy to expand market presence [12] Future Outlook - Analysts have raised GM's stock price target to $68, indicating recognition of the company's financial resilience and strategic pivot towards EV profitability [17] - The upcoming third-quarter earnings call on Oct. 21 will be crucial for assessing full-year guidance and adjusted automotive free cash flow [17]

Core Functionality - Quanto enables Raydium Protocol Liquidity Pool (LP) tokens as collateral [1] - Users can trade across 500+ markets using LP tokens as collateral [1] - Quanto aims to expand tradable and marginable assets, tokenizing and collateralizing everything on Solana [1] Benefits for Users - Users can continue earning yield from on-chain LP positions [2] - Users can actively trade markets without missing opportunities [2] - Users can hedge against impermanent loss using their own LP tokens [2] Capital Efficiency - Quanto unlocks a new layer of capital efficiency by turning LP tokens into collateral [1]

Key Metrics - Euler Finance's total borrows reached $2 billion [1] - Total deposits amounted to $4 billion [1] - Utilisation rate stands at 48% [1] Platform Efficiency - Euler Labs highlights the platform's flexibility and capital efficiency [1]

Core Insights - Greif, Inc. has successfully completed the sale of its timberlands business to Molpus Woodlands Group for $462 million, which will aid in debt reduction and enhance capital efficiency [1][2][7] Group 1: Timberlands Sale - The sale involves approximately 173,000 acres of timberlands located in the Southeastern United States [2][7] - This divestiture is part of Greif's ongoing portfolio optimization strategy, allowing the company to concentrate on its core business and invest in higher-margin markets [2][4] Group 2: Portfolio Optimization - In September, Greif also sold its containerboard business to Packaging Corporation of America, which includes two mills with a production capacity of 800,000 tons [3] - The cash proceeds from both sales are expected to reduce Greif's leverage ratio to below 1.2X, strengthening its balance sheet and generating interest savings [5][7] Group 3: Strategic Goals - The timberlands sale aligns with Greif's "Build to Last" strategy, marking a significant step towards improved capital efficiency and accelerated growth [4] - The company aims to reduce recurring capital expenditures, thereby unlocking value-creation opportunities [4] Group 4: Stock Performance - Greif's stock has increased by 0.7% over the past year, contrasting with a 14.3% decline in the industry [6]

DeFi Market Dynamics - Plasma launch represents a significant DeFi reset, challenging the first-mover advantage previously held by Ethereum-based protocols [1] - Capital is shifting towards platforms prioritizing security, innovation, and capital efficiency over established brand recognition [1] - Increased capital flow from Ethereum/L2s into Plasma is anticipated to narrow the valuation gap between older and newer DeFi tokens [2] Investment Opportunities - Aave leads in Total Value Locked (TVL), demonstrating its strong position in the DeFi landscape [1] - Fluid and Euler are highlighted as promising platforms due to their focus on capital efficiency, leading to higher yields for Liquidity Providers (LPs) [1] - $EUL and $FLUID are identified as potentially undervalued tokens with positive prospects [2]

RT Brother Lyskey (@0xLyskey)why this is giga-bullish for EkuboEkubo’s core challenge is that concentrated-liquidity pools demand constant, hands-on management. if your position goes out of range, your liquidity stops earning fees and becomes inactive.so to stay profitable you must rebalance frequently, especially because the tighter you concentrate around the active price, the more capital-efficient and fee-generating your position becomes.but doing this manually is hard and expensive, since Ekubo charges ...

Core Insights - CF Bankshares Inc. (CFBK) operates in a competitive banking landscape with peers such as Citizens Community Bancorp, Colony Bankcorp, Community West Bancshares, Citizens Holding Company, and C&F Financial Corporation [1] - CFBK's Return on Invested Capital (ROIC) is -1.19%, significantly below its Weighted Average Cost of Capital (WACC) of 24.98%, indicating inefficiencies in capital utilization [2][5] - The ROIC to WACC ratio for CFBK is -0.048, further emphasizing the company's struggle to generate returns relative to its capital costs [2] - Citizens Community Bancorp (CZWI) has a ROIC of 0.80% and a WACC of 18.82%, resulting in a ROIC to WACC ratio of 0.042, indicating low efficiency in capital utilization [3] - Colony Bankcorp (CBAN) shows a negative ROIC of -0.63% and a WACC of 12.69%, with a ROIC to WACC ratio of -0.050, reflecting similar inefficiencies as CFBK [3] - Community West Bancshares (CWBC) has a ROIC of 4.54% and a WACC of 11.57%, achieving a ROIC to WACC ratio of 0.392, indicating better capital efficiency [4] - C&F Financial Corporation (CFFI) stands out with a ROIC of 6.28% and a WACC of 13.55%, resulting in the highest ROIC to WACC ratio of 0.463 among peers, demonstrating superior capital efficiency [4][5]

Core Insights - AIM ImmunoTech Inc. is a biotechnology company focused on developing immune-based therapies, with its flagship product Ampligen being explored for multiple therapeutic applications [1] - AIM demonstrates exceptional capital efficiency with a Return on Invested Capital (ROIC) of 443.97%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.83%, resulting in a ROIC to WACC ratio of 76.10 [2][6] - In contrast, AIM's peers, including Aytu BioPharma, iBio, Co-Diagnostics, Cocrystal Pharma, and NanoViricides, show negative ROIC to WACC ratios, indicating inefficiencies in capital utilization [3][4][5][6] Company Performance - AIM's ROIC of 443.97% indicates effective use of capital to generate substantial returns, setting it apart from its peers in the biotechnology sector [2][6] - The company's ROIC to WACC ratio of 76.10 highlights its ability to generate returns far exceeding its cost of capital, showcasing strong capital efficiency [2][6] Peer Comparison - Aytu BioPharma has a ROIC of -2.78% and a WACC of 18.15, resulting in a negative ROIC to WACC ratio of -0.15, indicating capital inefficiency [3] - iBio reports a ROIC of -117.47% and a WACC of 6.80, leading to a negative ROIC to WACC ratio of -17.28, further illustrating struggles in capital efficiency [4] - Co-Diagnostics and Cocrystal Pharma also exhibit negative ROIC to WACC ratios of -13.01 and -13.80, respectively, highlighting ongoing challenges in generating adequate returns [4] - NanoViricides shows a ROIC of -111.71% and a WACC of 9.11, resulting in a negative ROIC to WACC ratio of -12.27, underscoring the difficulties faced by AIM's peers [5]